Search Result

Results for "

P110

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (8) Apoptosis (22) Autophagy (19) Bcl-2 Family (1) Biochemical Assay Reagents (1) Cadherin (1) Casein Kinase (4) CDK (1) DNA-PK (13) DNA/RNA Synthesis (1) Dynamin (4) GLUT (2) IFNAR (1) Influenza Virus (1) Molecular Glues (1) mTOR (14) Na+/K+ ATPase (1) Necroptosis (1) P-glycoprotein (1) PAK (1) PERK (1) PI3K (71) PIKfyve (1) PROTACs (2) Ras (4) Reactive Oxygen Species (ROS) (2) Reference Standards (17) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (67) Cardiovascular Disease (4) Infection (3) Inflammation/Immunology (7) Metabolic Disease (7) Neurological Disease (5)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50673

Dactolisib 65+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for *p110α/p110γ/p110δ/p110β* and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-50094

Pictilisib 65+ Cited Publications GDC-0941	PI3K Autophagy Apoptosis	Cancer
Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-17044

Duvelisib 15+ Cited Publications IPI-145; INK1197	PI3K	Cancer
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .

HY-70063

Buparlisib 85+ Cited Publications BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC₅₀s of 52, 166, 116 and 262 nM for *p110α, p110β, p110δ* and *p110γ*, respectively .

HY-13026

Idelalisib 55+ Cited Publications CAL-101; GS-1101	PI3K Autophagy	Cancer
Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable *p110δ* inhibitor with an IC₅₀ of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.

HY-10115

PI-103 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy .

HY-10297

Omipalisib 15+ Cited Publications GSK2126458; GSK458	PI3K mTOR Autophagy	Cancer
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .

HY-10108A

LY294002 hydrochloride Maximum Cited Publications 1119 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for *P110α, P110δ* and *P110β, respectively. LY294002 hydrochloride also inhibits CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

HY-13228

YM-201636 15+ Cited Publications	PIKfyve PI3K Autophagy Influenza Virus	Infection Cancer
YM-201636 is a potent and selective PIKfyve inhibitor with an IC₅₀ of 33 nM. YM-201636 also inhibits p110α with an IC₅₀ of 3.3 μM. YM-201636 inhibits retroviral replication.

HY-P10368

P110 heptapeptide	Dynamin Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-15900

Voxtalisib 5 Publications Verification XL765; SAR245409	PI3K mTOR	Cancer
Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC₅₀s=39, 113, 9 and 43?nM for *p110α, p110β, p110γ* and *p110δ, respectively), also inhibits DNA-PK (IC₅₀=150?nM) and mTOR (IC₅₀=157?nM). Voxtalisib (XL765) inhibits mTORC1* and mTORC2 with IC₅₀s of 160 and 910 nM, respectively.

HY-P2280

TAT-P110 P110	Dynamin	Neurological Disease Inflammation/Immunology
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-13281

PIK-75 hydrochloride 5 Publications Verification	DNA-PK PI3K Apoptosis	Cancer
PIK-75 hydrochloride is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, *p110α* and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 hydrochloride induces apoptosis .

HY-15245

GSK2636771 5+ Cited Publications	PI3K	Cancer
GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K_i of 0.89 nM and an IC₅₀ of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-P6437A

*Drp1 peptide inhibitor P110* TFA**	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-12030

PIK-90 5 Publications Verification	PI3K DNA-PK	Cancer
PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits *p110α, p110γ* and DNA-PK with IC₅₀s of 11, 18 and 13 nM, respectively.

HY-10114

TGX-221 15+ Cited Publications	PI3K	Cancer
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, used for cancer treatment.

HY-173405

VVD-699	Ras PI3K Akt	Cancer
VVD-699 is a covalent blocker of the *RAS-p110α* interaction with oral activity. VVD-699 inhibits activation of PI3Kα (IC₅₀: 104 nM in H358 cells) . VVD-699 inhibits phosphorylated AKT. VVD-699 can be used for the research of KRAS mutant/amplified cancer .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-10115A

PI-103 Hydrochloride 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-20180

Pictilisib dimethanesulfonate 65+ Cited Publications GDC-0941 dimethanesulfonate ; GDC-0941 (2 MeSO3H salt)	PI3K Autophagy Apoptosis	Cancer
Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-N6775

Sonolisib 1 Publications Verification PX-866	PI3K	Cancer
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC₅₀=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .

HY-10344

AZD 6482 20+ Cited Publications KIN-193	PI3K Autophagy	Cancer
AZD 6482 (KIN-193) is a potent and selective *p110β* inhibitor with an IC₅₀ of 0.69 nM.

HY-15180

Buparlisib Hydrochloride 85+ Cited Publications BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for *p110α/p110β/p110δ/p110γ*, respectively.

HY-107834

PIK-75 5 Publications Verification	DNA-PK PI3K Apoptosis	Cancer
PIK-75 is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 induces apoptosis .

HY-12235

PI-3065 4 Publications Verification	PI3K	Inflammation/Immunology Cancer
PI-3065 is a potent inhibitor of PI3K p110δ, with IC₅₀ and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC₅₀s of 910, 600, >10000 nM.

HY-12285

Serabelisib MLN1117; INK1117; TAK-117	PI3K	Cancer
Serabelisib (MLN1117) is a selective *p110α* inhibitor with an IC₅₀ of 15 nM.

HY-13261

A66 3 Publications Verification	PI3K	Cancer
A66 is a highly specific and selective *p110α* inhibitor with an IC₅₀ of 32 nM.

HY-W1126235

DS02312223 D223	Molecular Glues Ras PI3K GLUT	Metabolic Disease
DS02312223 (D223) is a molecular glue that promotes the binding of RAS to PI3Kα, with a K_d of 0.76 μM for *p110α. DS02312223 increases the binding affinity between GTP-bound KRAS (KRAS-GMPPNP) and p110α by nearly three orders of magnitude (K_D* = 0.017 μM). DS02312223 stimulates the translocation of GLUT4 to the plasma membrane. DS02312223 promotes glucose uptake in the absence of insulin. DS02312223 can be used in diabetes research .

HY-176811

VVD-442	Ras PI3K Akt	Cancer
VVD-442 is an inhibitor targeting PI3Kα. VVD-442 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α, induces conformational changes, and disrupts the interaction between PI3K p110α and RAS proteins. VVD-442 also blocks RAS-mediated PI3K activation. VVD-442 can be used in research related to RAS-mutant cancers and HER2-overexpressing cancers .

HY-108606

PI-828 2 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for *p110α, CK2, and CK2α2* in lipid kinase assay, respectively .

HY-176812

VVD-849	Ras PI3K Akt	Cancer
VVD-849 is a RAS ligand. VVD-849 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α and promotes RAS/PI3K interaction. VVD-849 partially inhibits pAKT (S473) in HER2-overexpressing tumors. VVD-849 can be used for the research of cancers such as breast cancer .

HY-10303

PIK-294 2 Publications Verification	PI3K	Cancer
PIK-294 is a potent *p110δ*-selective inhibitor with an IC₅₀ of 10 nM.

HY-156371

MIPS-21335	PI3K	Cardiovascular Disease Metabolic Disease
MIPS-21335 is a PI3KC2α inhibitor with an IC₅₀ of 7 nM. MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ, with IC₅₀ values of 43, 140, 386 and 742 nM, respectively. MIPS-21335 has antithrombotic effect. MIPS-21335 can be used for the researches of cardiovascular disease and metabolic disease, such as thrombosis and hyperlipidemia .

HY-50094R

Pictilisib (Standard) GDC-0941 (Standard)	PI3K Autophagy Apoptosis Reference Standards	Cancer
Pictilisib (Standard) is the analytical standard of Pictilisib. This product is intended for research and analytical applications. Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

HY-114428

P110δ-IN-1	PI3K	Cancer
P110δ-IN-1 is a potent and selective inhibitor of *P110δ* extracted from patent WO 2014055647 A1, with an IC₅₀ of 8.4 nM .

HY-15244R

Alpelisib (Standard) BYL-719 (Standard)	Reference Standards PI3K Apoptosis	Cancer
Alpelisib (Standard) is the analytical standard of Alpelisib. This product is intended for research and analytical applications. Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity .

HY-111184

PIK-108	PI3K	Cancer
PIK-108 is a non-ATP competitive, allosteric *p110β/p110δ* selective inhibitor .

HY-75124

(Rac)-AZD 6482 1 Publications Verification (Rac)-KIN-193	PI3K Autophagy	Cancer
(Rac)-AZD 6482 ((Rac)-KIN-193) is the racemate of AZD 6482. AZD 6482 is a potent and selective p110β inhibitor with an IC₅₀ of 0.69 nM.

HY-17044R

Duvelisib (Standard) IPI-145 (Standard); INK1197 (Standard)	PI3K Reference Standards	Cancer
Duvelisib (Standard) is the analytical standard of Duvelisib. This product is intended for research and analytical applications. Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .

HY-124535

TGX-115	PI3K	Metabolic Disease
TGX-115 is a p110β/p110δ-selective, PI3-K inhibitor. TGX-115 blocks p110β-mediated Akt phosphorylation induced by lysophosphatidic acid (LPA) in L6 myotubes, reduces insulin-stimulated PI(3,4)P2 and PIP3 levels in 3T3-L1 adipocytes. TGX-115 can be used for the study of diabetes mellitus .

HY-50673A

Dactolisib hydrochloride 60+ Cited Publications BEZ235 hydrochloride; NVP-BEZ235 hydrochloride	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for *p110α*/γ/δ/β and mTOR with IC₅₀ of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .

HY-111510

IPI-3063	PI3K	Inflammation/Immunology
IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC₅₀ of 2.5 ± 1.2 nM.

HY-RS03369

CUX1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CUX1 Human Pre-designed siRNA Set A contains three designed siRNAs for CUX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CUX1 Human Pre-designed siRNA Set A CUX1 Human Pre-designed siRNA Set A

HY-13504

PIK-293 1 Publications Verification	PI3K	Metabolic Disease Cancer
PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC₅₀ values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .

HY-150309

PI3K-IN-54	PI3K	Cancer
PI3K-IN-54 (compound 10w) is a pan-PI3K inhibitor. The IC₅₀ values of PI3K-IN-54 for p110α, p110β, and p110δ are 0.22 nM, 1.4 nM, and 0.38 nM, respectively. PI3K-IN-54 can be used in cancer research .

HY-13026S

Idelalisib-d5 CAL-101 d₅; GS-1101 d₅	PI3K Autophagy	Cancer
Idelalisib-d₅ is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor .

HY-174469

*PROTAC PI3K/110β degrader-2*	PROTACs P-glycoprotein Apoptosis Reactive Oxygen Species (ROS) Akt Bcl-2 Family Na+/K+ ATPase PI3K	Cancer
PROTAC PI3K/110β degrader-2 is a selective PI3K/p110β PROTAC degrader. PROTAC PI3K/110β degrader-2 can significantly degrade *110β* protein and inhibit the expression of P-glycoprotein. PROTAC PI3K/110β degrader-2 can increase the level of reactive oxygen species (ROS). PROTAC PI3K/110β degrader-2 exerts anti-tumor effects by activating the endoplasmic reticulum stress (ERS)-mediated mitochondrial apoptosis pathway and inhibiting the AKT/Bcl-2 signaling pathway. PROTAC PI3K/110β degrader-2 can be used for research on cancer. (Pink: PI3K/110β Ligand (HY-75124); Blue: VHL Ligand (HY-125845); Black: Linker (HY-W002042)) .

HY-100706

AMA-37	DNA-PK	Cancer
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC₅₀ values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P10368

P110 heptapeptide	Dynamin Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .

HY-P2280

TAT-P110 P110	Dynamin	Neurological Disease Inflammation/Immunology
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

HY-P6437A

*Drp1 peptide inhibitor P110* TFA**	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

Species:	Human (17)
Tag:	SUMO (1) His (8) Strep (5) Tag Free (2) Avi (6) Myc (1) GST (2)
Source:	Sf9 insect cells (14) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705511

	OGT Protein, Human (His, Myc) O-GlcNAc transferase subunit P110; O-linked N-acetylglucosamine transferase 110 kDa subunit	Human	E. coli

HY-P703650

	OGT Protein, Human (His) 1 Publications Verification UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit; O-GlcNAc transferase subunit P110; O-linked N-acetylglucosamine transferase 110 kDa subunit (OGT); OGT	Human	E. coli
	OGT Protein, Human (His) is the recombinant human-derived OGT protein, expressed by E. coli, with N-6*His & N-SUMO tag.

HY-P701515

	TCEB3 Protein, Human (sf9) ELOA (TCEB3); Elongin-A; EloA; Elongin 110 kDa subunit; RNA polymerase II transcription factor SIII subunit A1; SIII P110; Transcription elongation factor B polypeptide 3	Human	Sf9 insect cells
	TCEB3, also known as SIII, acts as a key transcription elongation factor that promotes RNA polymerase II progression beyond the blocking site. It interacts with SIII regulatory subunits B and C to form the elongin BC complex, which significantly enhances the transcriptional activity of subunit A. TCEB3 Protein, Human (sf9) is the recombinant human-derived TCEB3 protein, expressed by sf9 insect cells , with tag free.

HY-P701514

	TCEB3 Protein, Human (sf9, His, StrepⅡ) ELOA (TCEB3); Elongin-A; EloA; Elongin 110 kDa subunit; RNA polymerase II transcription factor SIII subunit A1; SIII P110; Transcription elongation factor B polypeptide 3	Human	Sf9 insect cells
	TCEB3, also known as SIII, acts as a key transcription elongation factor that promotes RNA polymerase II progression beyond the blocking site. It interacts with SIII regulatory subunits B and C to form the elongin BC complex, which significantly enhances the transcriptional activity of subunit A. TCEB3 Protein, Human (sf9, His, Strep) is the recombinant human-derived TCEB3 protein, expressed by sf9 insect cells , with N-Strep, N-8*His labeled tag.

HY-P703583

	*p85/p110* Protein, Human (Active, sf9)** GRB1	Human	Sf9 insect cells

HY-P703467

	*p85/p110* Protein, Human (Active, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells

HY-P705593

	*p85 alpha/p110* beta Protein, Human (Active, sf9, His)** GRB1	Human	Sf9 insect cells

HY-P703466

	*p85/p110* Protein, Human (Active, H1047R, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells

HY-P703468

	*p85/p110* Protein, Human (Active, E542K, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, E542K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703469

	*p85/p110* Protein, Human (Active, E545K, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, E545K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703470

	*p85/p110* Protein, Human (Active, N345K, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, N345K, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703471

	*p85/p110* Protein, Human (Active, P539R, Biotinylated, sf9, Avi)** GRB1	Human	Sf9 insect cells
	p85/p110 Protein, Human (Active, P539R, Biotinylated, sf9, Avi) is the recombinant human-derived p85/p110, expressed by sf9 insect cells , with Avi labeled tag. ,

HY-P703581

	PK3CD/p85 Protein, Human (Active, sf9, His, Strep, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit P110-delta; P110delta; PIK3CD; Homo sapiens; Human; PI3-kinase subunit delta; Kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PK3CD/p85 Protein, Human (Active, sf9, His, Strep, GST) is the recombinant human-derived PK3CD/p85, expressed by sf9 insect cells , with Strep, His, GST labeled tag. ,

HY-P703588

	RB1 Protein, Human (StrepⅡ) Retinoblastoma-associated protein; p105-Rb; P110-RB1; pRb; Rb; pP110; RB1; Homo sapiens; Human; Rb; Chromatin regulator; DNA-binding; Repressor	Human	E. coli
	RB1 Protein, Human (Strep) is the recombinant human-derived RB1, expressed by E. coli , with Strep labeled tag. ,

HY-P703582

	PIK3CG Protein, Human (sf9, His, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PtdIns-3-kinase subunit P110-gamma; P110gamma; Phosphoinositide-3-kinase catalytic gamma polypeptide; Serine/threonine protein kinase PIK3CG; 2.7.11.1; p120-PI3K; PIK3CG; Homo sapiens; Human; PI3-kinase subunit gamma; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CG Protein, Human (sf9, His, GST) is the recombinant human-derived PIK3CG, expressed by sf9 insect cells , with His, GST labeled tag. ,

HY-P705719

	PIK3CA Protein, Human (sf9, His, StrepⅡ) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit P110-alpha; P110alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase PIK3CA; 2.7.11.1; PIK3CA; Homo sapiens; Human; PI3-kinase subunit alpha; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CA Protein, Human (sf9, His, StrepⅡ) is the recombinant human-derived PIK3CA, expressed by sf9 insect cells , with Strep, His labeled tag.

HY-P703580

	PIK3CA Protein, Human (Active, H1047R, sf9, His, StrepⅡ) 1 Publications Verification Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit P110-alpha; P110alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase PIK3CA; 2.7.11.1; PIK3CA; Homo sapiens; Human; PI3-kinase subunit alpha; Kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CA Protein, Human (Active, H1047R, sf9, His, StrepⅡ) is the recombinant human-derived PIK3CA, expressed by sf9 insect cells , with Strep, His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (1) Rabbit (10)
Reactivity:	Human (11) Rat (10) Mouse (10)
Application:	IHC-P (2) ICC/IF (10) IP (7) IHC-F (1) WB (11) FC (2) ELISA (3)
Isotype:	IgG, Kappa (1) IgG (9) IgG1 (1)
Conjugation:	Non-conjugated (11) Biotin (6)
Clonality:	Polyclonal (1) Monoclonal (8) Recombinant (5)
Modification:	Phosphorylated (1) Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86116

	*PI3-Kinase p110* β Antibody (YA5808)** 1 Publications Verification	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3-Kinase p110 β Antibody (YA5808) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3-Kinase p110 β.

HY-P81162

	*PI3 Kinase p110* alpha/PIK3CA Antibody (YA3537)** PI3 kinase P110 subunit alpha; caPI3K; MGC142161; MGC142163; P110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase P110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase P110; PI3-kinase P110α; PI3-kinase P110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81162A

	*PI3 Kinase p110* alpha/PIK3CA Antibody (PBS only)** PI3 kinase P110 subunit alpha; caPI3K; MGC142161; MGC142163; P110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase P110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase P110; PI3-kinase P110α; PI3-kinase P110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P83439

	Protein CASP Antibody (YA3184) CDP; CUX; p75; CASP; CDP1; COY1; Clox; GDDI; p100; P110; p200; CUTL1; GOLIM6; CDP/Cut; Cux/CDP; Nbla10317	WB, ICC/IF, FC, IP	Human, Mouse, Rat
	Protein CASP Antibody (YA3184) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Protein CASP.

HY-P83439A

	Protein CASP Antibody (YA3184)(PBS only) CDP; CUX; p75; CASP; CDP1; COY1; Clox; GDDI; p100; P110; p200; CUTL1; GOLIM6; CDP/Cut; Cux/CDP; Nbla10317	WB, ICC/IF, FC, IP	Human, Mouse, Rat
	Protein CASP Antibody (YA3184) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Protein CASP.

HY-P80865

	*PI3 Kinase p110* gamma Antibody (YA690)** 1 Publications Verification PI3K; PIK3; PI3CG; PI3Kgamma; P110gamma; p120-PI3K	WB	Human
	PI3 Kinase p110 gamma Antibody (YA690) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PI3 Kinase p110 gamma.

HY-P81211

	*phospho-PI3 Kinase p110* beta (Ser1070) Antibody** Maximum Cited Publications 6 Publications Verification PI3-kinase P110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; P110 BETA; P110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase P110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; Pik3cb; PK3CB_HUMAN; PtdIns 3 kinase P110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit P110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	phospho-PI3 Kinase p110 beta (Ser1070) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to phospho-PI3 Kinase p110 beta (Ser1070).

HY-P86078

	*PI3 Kinase p110* alpha/PIK3CA Antibody (YA5770)** 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; 5-bisphosphate 3-kinase catalytic subunit alpha isoform; caPI3K; CLOVE; CWS5; MCAP; MCM; MCMTC; MGC142161; MGC142163; P110 alpha; P110alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI 3 Kinase catalytic subunit alpha; PI3 kinase P110 subunit alpha; PI3-kinase subunit alpha; PI3K; PI3K-alpha; PI3KC A; PIK3C A; Pik3ca; PK3CA; PK3CA_HUMAN; PtdIns 3 kinase P110; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit P110-alpha; Serine/threonine protein kinase PIK3CA	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81872

	*PI3 Kinase p110* delta Antibody (YA1617)** PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit P110-delta; P110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 delta.

HY-P81872A

	*PI3 Kinase p110* delta Antibody (YA1617)(PBS only)** PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit P110-delta; P110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 delta.

HY-P87775

	*PI3-Kinase p110γ Antibody (YA7460)*	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3-Kinase p110γ Antibody (YA7460) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to PI3-Kinase p110γ.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: